1. Neonatal Cytomegalovirus Infection: Advocacy, Legislation, and Changing Practice.
- Author
-
Stark A, Crooks CM, Permar SR, and Weimer KED
- Subjects
- Humans, Infant, Newborn, United States, Antiviral Agents therapeutic use, Pregnancy Complications, Infectious epidemiology, Pregnancy Complications, Infectious therapy, Infectious Disease Transmission, Vertical prevention & control, Hearing Loss, Sensorineural, Pregnancy, Female, Cost-Benefit Analysis, Cytomegalovirus Infections congenital, Neonatal Screening
- Abstract
Cytomegalovirus (CMV) is the most common intrauterine infection. While only 10% to 15% of infants display symptoms at birth, 25% of infants with congenital CMV (cCMV) will develop sequelae such as sensorineural hearing loss and neurodevelopmental impairment by the age of 2 years. Although antiviral therapy and early intervention services can improve outcomes for infected infants, cCMV has a substantial economic impact. Studies show that both targeted and universal screenings are cost-effective, but targeted screening misses many infected infants at risk for sequelae. The state-based approach to cCMV screening in the United States varies from universal, targeted, education only to no requirements., Competing Interests: Disclosure S.R. Permar serves as a consultant to Merck, Pfizer, Moderna, Dynavax, GSK, and Hookipa CMV vaccine programs and leads sponsored vaccine programs with Moderna and Merck., (Copyright © 2024 Elsevier Inc. All rights reserved.)
- Published
- 2025
- Full Text
- View/download PDF